Multi-CBV vaccine for preventing or treating type 1 diabetes

A method of inducing an immune response to coxsackie B virus (CBV) in a pregnant woman, the method comprising administering to the pregnant woman an effective amount of a composition comprising:

• a) CBV1 and CBV2 in inactivated form or in the form of a subunit or a virus-like particle (VLP);
• and
• b) at least one CBV selected from CBV3, CBV4, CBV5, and CBV6 in inactivated form or in the form of a subunit or a VLP,
• wherein the composition does not include any enterovirus or enterovirus VLP other than a CBV virus or CBV VLP, wherein the method does not comprise administering any enterovirus or enterovirus VLP other than a CBV virus or a CBV VLP, and
• wherein said administering induces an immune response to CBV in the pregnant woman.

A method of inducing an immune response to coxsackie B virus (CBV) in an individual who is a carrier of an HLA DR3 and/or DR4 allele, the method comprising administering to the individual an effective amount of a composition comprising:

• a) CBV1 and CBV2 in inactivated form or in the form of a subunit or a virus-like particle (VLP);
• and
• b) at least one CBV selected from CBV3, CBV4, CBV5, and CBV6 in inactivated form or in the form of a subunit or a VLP,
• wherein the composition does not include any enterovirus or enterovirus VLP other than a CBV virus or CBV VLP, wherein the method does not comprise administering any enterovirus or enterovirus VLP other than a CBV virus or a CBV VLP, and
• wherein said administering induces an immune response to CBV in the individual.

A method of inducing an immune response to coxsackie B virus (CBV) in an individual at increased risk of developing type 1 diabetes, the method comprising administering to the individual an effective amount of a composition consisting of:

• a) CBV1 and CBV2 in inactivated form or in the form of a subunit or a virus-like particle (VLP);
• and
• b) at least one CBV selected from CBV3, CBV4, CBV5, and CBV6 in inactivated form or in the form of a subunit or a VLP,
• wherein the method does not comprise administering any enterovirus or enterovirus VLP other than a CBV virus or a CBV VLP, and
• wherein said administering induces an immune response to CBV in the individual.

A method of inducing an immune response to coxsackie B virus (CBV) in a pregnant woman, the method comprising administering to the pregnant woman an effective amount of a composition consisting of:

• a) CBV1 and CBV2 in inactivated form or in the form of a subunit or a virus-like particle (VLP);
• and
• b) at least one CBV selected from CBV3, CBV4, CBV5, and CBV6 in inactivated form or in the form of a subunit or a VLP,
• wherein the composition does not include any enterovirus or enterovirus VLP other than a CBV virus or CBV VLP, wherein the method does not comprise administering any enterovirus or enterovirus VLP other than a CBV virus or a CBV VLP, and
• wherein said administering induces an immune response to CBV in the pregnant woman.

A method of inducing an immune response to coxsackie B virus (CBV) in an individual who is a carrier of an HLA DR3 and/or DR4 allele, the method comprising administering to the individual an effective amount of a composition consisting of:

• a) CBV1 and CBV2 in inactivated form or in the form of a subunit or a virus-like particle (VLP);
• and
• b) at least one CBV selected from CBV3, CBV4, CBV5, and CBV6 in inactivated form or in the form of a subunit or a VLP,
• wherein the composition does not include any enterovirus or enterovirus VLP other than a CBV virus or CBV VLP, wherein the method does not comprise administering any enterovirus or enterovirus VLP other than a CBV virus or a CBV VLP, and
• wherein said administering induces an immune response to CBV in the individual.